Production (Stage)
Chemomab Therapeutics Ltd.
CMMB
$1.23
$0.032.50%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -68.33% | -47.84% | -38.75% | 38.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -53.13% | -36.59% | -10.77% | 101.79% |
| Operating Income | -- | 53.13% | 36.59% | 10.77% | -101.79% |
| Income Before Tax | -- | 54.40% | 39.14% | 14.05% | -100.33% |
| Income Tax Expenses | -- | -184.62% | 95.91% | 100.00% | -- |
| Earnings from Continuing Operations | -- | 54.66% | 38.21% | 12.39% | -97.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 54.66% | 38.21% | 12.39% | -97.10% |
| EBIT | -- | 53.13% | 36.59% | 10.77% | -101.79% |
| EBITDA | -- | 53.23% | 36.68% | 10.83% | -101.91% |
| EPS Basic | -- | 61.59% | 42.38% | 12.83% | -97.42% |
| Normalized Basic EPS | -- | 82.47% | 65.30% | 28.61% | -100.60% |
| EPS Diluted | -- | 61.59% | 42.38% | 12.83% | -97.42% |
| Normalized Diluted EPS | -- | 82.47% | 65.30% | 28.61% | -100.60% |
| Average Basic Shares Outstanding | -- | 18.98% | 10.99% | 3.19% | 0.32% |
| Average Diluted Shares Outstanding | -- | 18.99% | 10.99% | 3.19% | 0.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |